BioCentury | Dec 15, 2018
Politics & Policy

Firdapse re-catalyzes pricing debate

...for companies to charge prices that the public finds unconscionable. This happened in 2010, when URL Pharma Inc....
BioCentury | Sep 12, 2016
Politics, Policy & Law

Executive power

...decision. In 2009, Sharfstein held up FDA approval of Colcrys colchicine, a gout therapy, until URL Pharma Inc....
BioCentury | Jan 18, 2016
Politics, Policy & Law

Compounding prices

...administration, prompting fierce debates within FDA both times. In 2009, FDA reviewed an application from URL Pharma Inc....
BioCentury | Oct 13, 2014
Strategy

Streamlining Takeda's Profit Story

...been on the same scale as the Millennium and Nycomed deals. The 2012 acquisition of URL Pharma Inc....
BioCentury | Sep 23, 2013
Clinical News

Colchicine: Phase III data

...Azienda Sanitaria Locale 3. Data were published in the New England Journal of Medicine. Takeda's URL Pharma Inc....
BioCentury | Jul 1, 2013
Company News

Sun Pharmaceutical inflammation, generics news

...epidermal necrolysis (TEN) in 2004 after receiving the generic NSAID sulindac manufactured by Mutual, now URL Pharma Inc....
BioCentury | Jun 25, 2013
Politics & Policy

SCOTUS further restricts generics suits

...the ability of patients to hold generic drug manufacturers liable for injuries. In a 5-4 URL Pharma Inc....
BioCentury | Mar 25, 2013
Company News

Sun Pharmaceutical inflammation, generics news

...epidermal necrolysis (TEN) in 2004 after receiving the generic NSAID sulindac manufactured by Mutual, now URL Pharma Inc....
BioCentury | Mar 20, 2013
Top Story

SCOTUS hears preemption oral arguments

...epidermal necrolysis (TEN) in 2004 after receiving the generic NSAID sulindac manufactured by Mutual, now URL Pharma Inc....
BioCentury | Dec 24, 2012
Company News

Sun Pharmaceutical, Takeda deal

...Sun's Caraco Pharmaceutical Laboratories Ltd. subsidiary will acquire the non- Colcrys colchicine assets of Takeda's URL Pharma Inc....
...retain ownership of the gout drug and be exclusively responsible for its commercialization. Takeda acquired URL Pharma...
Items per page:
1 - 10 of 32
BioCentury | Dec 15, 2018
Politics & Policy

Firdapse re-catalyzes pricing debate

...for companies to charge prices that the public finds unconscionable. This happened in 2010, when URL Pharma Inc....
BioCentury | Sep 12, 2016
Politics, Policy & Law

Executive power

...decision. In 2009, Sharfstein held up FDA approval of Colcrys colchicine, a gout therapy, until URL Pharma Inc....
BioCentury | Jan 18, 2016
Politics, Policy & Law

Compounding prices

...administration, prompting fierce debates within FDA both times. In 2009, FDA reviewed an application from URL Pharma Inc....
BioCentury | Oct 13, 2014
Strategy

Streamlining Takeda's Profit Story

...been on the same scale as the Millennium and Nycomed deals. The 2012 acquisition of URL Pharma Inc....
BioCentury | Sep 23, 2013
Clinical News

Colchicine: Phase III data

...Azienda Sanitaria Locale 3. Data were published in the New England Journal of Medicine. Takeda's URL Pharma Inc....
BioCentury | Jul 1, 2013
Company News

Sun Pharmaceutical inflammation, generics news

...epidermal necrolysis (TEN) in 2004 after receiving the generic NSAID sulindac manufactured by Mutual, now URL Pharma Inc....
BioCentury | Jun 25, 2013
Politics & Policy

SCOTUS further restricts generics suits

...the ability of patients to hold generic drug manufacturers liable for injuries. In a 5-4 URL Pharma Inc....
BioCentury | Mar 25, 2013
Company News

Sun Pharmaceutical inflammation, generics news

...epidermal necrolysis (TEN) in 2004 after receiving the generic NSAID sulindac manufactured by Mutual, now URL Pharma Inc....
BioCentury | Mar 20, 2013
Top Story

SCOTUS hears preemption oral arguments

...epidermal necrolysis (TEN) in 2004 after receiving the generic NSAID sulindac manufactured by Mutual, now URL Pharma Inc....
BioCentury | Dec 24, 2012
Company News

Sun Pharmaceutical, Takeda deal

...Sun's Caraco Pharmaceutical Laboratories Ltd. subsidiary will acquire the non- Colcrys colchicine assets of Takeda's URL Pharma Inc....
...retain ownership of the gout drug and be exclusively responsible for its commercialization. Takeda acquired URL Pharma...
Items per page:
1 - 10 of 32